Telehealth & Digital Health

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

As US organ donor registrations fall, Southern Legacy of Life achieves its second-best year, saving hundreds through strategic community engagement.

A first-in-class oral therapy targeting cellular metabolism has entered patient trials, offering new hope for a disease-modifying treatment for eczema.

As consolidation reshapes healthcare, Integrated Dermatology's new CMO appointment signals a strategic move to blend clinical leadership with corporate growth.

A new partnership brings vital mental health screenings and support directly to NICU parents, addressing a hidden crisis with long-term benefits for families.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

A new FDA-cleared test detects RSV, Flu A/B, and COVID from a single swab, offering a powerful diagnostic tool for families, especially for infants.

New 24-month data suggests a novel drug could improve kidney function and reduce side effects for transplant patients, challenging a decades-old standard.

Ossium Health's groundbreaking study using banked bone marrow from deceased donors could solve the critical shortage of transplant matches for patients.

A new strategic partnership aims to dismantle commercialization hurdles, promising faster access to life-saving therapies for rare disease patients.

SPR Therapeutics unveils 12-month data at NANS 2026, showing its temporary SPRINT PNS system provides durable pain relief without a permanent implant.

With $287M in new funding, Corxel Pharmaceuticals aims to disrupt the obesity market with its oral GLP-1 drug, CX11, and a diverse cardiometabolic pipeline.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

A new AI system scans IDs to identify high-risk individuals in real-time, but raises questions about the balance between hospital safety and privacy.

The virtual ABA therapy leader aims to slash costs and wait times with its AI platform that delivers results in 85% fewer hours than traditional methods.

An innovative absorbable implant shows promise in helping men regain continence faster after prostate cancer surgery, a major quality-of-life concern.

A new AAAHC-accredited surgery center in Tarzana offers advanced spine and joint care, reflecting a national trend toward safer, cost-effective procedures.